Information

Related Research Units

Dana Farber Boston Childrens Cancer and Blood Disorders Center Research
Hematology and Oncology Research

Research Overview

Dr. Nathan no longer operates a research laboratory. Most of his academic effort is devoted to teaching students, house staff and fellows, mentoring young faculty members, and writing text book chapters, books and short articles. He continues his interest in the congenital and acquired bone marrow failure syndromes and the hemoglobinopathies. He has recently received three program project grants of which he is the PI devoted to an entirely new treatment of sickle cell crisis based on interference with iNKT cell function. He remains involved in policies concerning clinical research.

 

Research Background

David Nathan received an MD from Harvard Medical School. He completed an internship and residency at Brigham and Women's Hospital and a fellowship at the National Cancer Institute.

David Nathan received an MD from Harvard Medical School. He completed an internship and residency at Brigham and Women's Hospital and a fellowship at the National Cancer Institute.

He is the recipient of numerous awards, including the National Medal of Science, 1990; the American Philosophical Society, 1999; the Annual Award for Excellence in Clinical Research, NIH, 1996; the Henry Stratton Medal, American Society of Hematology, 1995; the John Howland Medal of the American Pediatric Society, 2003; the George Kober Medal of the Association of American Physicians, 2006; John Stearns Medal for Life Time Achievement in Medicine, 2009; Harvard University Honorary Doctor of Science, 2010; and the Wallace H. Coulter Award, American Society of Hematology, 2011.

Education

Medical School

Harvard Medical School
Boston MA

Internship

Brigham and Women's Hospital
Boston MA

Residency

Brigham and Women's Hospital
Boston MA

Fellowship

Brigham and Women's Hospital
Bethesda MD

Publications

  1. Correcting the record on anemia of aging: a statistical reanalysis. Blood Adv. 2023 07 25; 7(14):3642-3643. View Abstract
  2. COVID-19, nuclear war, and global warming: lessons for our vulnerable world. Lancet. 2020 06 27; 395(10242):1967-1968. View Abstract
  3. The Genetic Landscape of Diamond-Blackfan Anemia. Am J Hum Genet. 2018 12 06; 103(6):930-947. View Abstract
  4. The Pathophysiology of Acquired Aplastic Anemia: Current Concepts Revisited. Hematol Oncol Clin North Am. 2018 Aug; 32(4):581-594. View Abstract
  5. Training. Pediatr Blood Cancer. 2018 02; 65(2). View Abstract
  6. Cholesterol: the debate should be terminated. FASEB J. 2017 07; 31(7):2722-2728. View Abstract
  7. Eulogy for the clinical research center. J Clin Invest. 2016 07 01; 126(7):2388-91. View Abstract
  8. Thalassemia: a look to the future. Ann N Y Acad Sci. 2016 03; 1368(1):11-5. View Abstract
  9. Amino acid uptake in erythropoiesis. Sci Signal. 2015 Apr 14; 8(372):fs9. View Abstract
  10. A conversation with David Nathan. J Clin Invest. 2014 Dec; 124(12):5090-1. View Abstract
  11. Hereditary xerocytosis revisited. Am J Hematol. 2014 Dec; 89(12):1142-6. View Abstract
  12. A tribute to Emil Frei III. J Clin Invest. 2013 Aug 1; 123(8):3188-9. View Abstract
  13. Pathophysiology and Clinical Manifestations of the ß-Thalassemias. Cold Spring Harb Perspect Med. 2012 Dec 01; 2(12):a011726. View Abstract
  14. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012 Jul; 122(7):2439-43. View Abstract
  15. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc. 2012; 123:312-7; discussion 317-8. View Abstract
  16. Fetal hemoglobin levels and morbidity in untransfused patients with ß-thalassemia intermedia. Blood. 2012 Jan 12; 119(2):364-7. View Abstract
  17. Guilt by association. Blood. 2011 Oct 06; 118(14):3758-9. View Abstract
  18. Reversing the hemoglobin switch. N Engl J Med. 2010 Dec 02; 363(23):2258-60. View Abstract
  19. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010 Dec; 24(6):1005-20. View Abstract
  20. A life-long quest to understand and treat genetic blood disorders. Cell. 2010 Oct 01; 143(1):17-20. View Abstract
  21. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010 Aug 05; 116(5):687-92. View Abstract
  22. Musings on genome medicine: Hepatitis C. Genome Med. 2010 Jan 27; 2(1):4. View Abstract
  23. Sickle cell disease and stroke. Blood. 2009 Dec 10; 114(25):5117-25. View Abstract
  24. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases. Genome Med. 2009 Dec 09; 1(12):114. View Abstract
  25. Musings on genome medicine: Crohn's disease. Genome Med. 2009 Nov 05; 1(11):103. View Abstract
  26. Musings on genome medicine: the slow but inexorable process of medical care reform in the United States. Genome Med. 2009 Oct 12; 1(10):94. View Abstract
  27. Call for a slower approach to health care reform. J Clin Invest. 2009 Oct; 119(10):2847-8. View Abstract
  28. Musings on genome medicine: the Obama effect redux. Genome Med. 2009 Sep 11; 1(9):86. View Abstract
  29. Musings on genome medicine: cholesterol and coronary artery disease. Genome Med. 2009 Jun 08; 1(6):60. View Abstract
  30. Musings on genome medicine: cancer genetics and the promise of effective treatment. Genome Med. 2009 May 06; 1(5):49. View Abstract
  31. Musings on genome medicine: gene therapy. Genome Med. 2009 Apr 03; 1(4):38. View Abstract
  32. Musings on genome medicine: the Obama effect. Genome Med. 2009 Mar 09; 1(3):30. View Abstract
  33. Musings on genome medicine: abuse of genetic tests. Genome Med. 2009 Feb 16; 1(2):18. View Abstract
  34. Musings on genome medicine: genome wide association studies. Genome Med. 2009 Jan 20; 1(1):3. View Abstract
  35. Judah Folkman, MD, 1933-2008. Pharos Alpha Omega Alpha Honor Med Soc. 2009; 4-8. View Abstract
  36. Targeting the cell death-survival equation. Clin Cancer Res. 2007 Dec 15; 13(24):7250-3. View Abstract
  37. Stanley J. Korsmeyer. Proc Am Philos Soc. 2007 Jun; 151(2):243-6. View Abstract
  38. Acceptance of the 2006 Kober medal. J Clin Invest. 2007 Apr; 117(4):1107-13. View Abstract
  39. The cancer treatment revolution. Trans Am Clin Climatol Assoc. 2007; 118:317-23. View Abstract
  40. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006 Dec; 79(6):1110-8. View Abstract
  41. NIH support for basic and clinical research: biomedical researcher angst in 2006. JAMA. 2006 Jun 14; 295(22):2656-8. View Abstract
  42. The several Cs of translational clinical research. J Clin Invest. 2005 Apr; 115(4):795-7. View Abstract
  43. New developments in iron chelators. Curr Opin Hematol. 2005 Mar; 12(2):129-34. View Abstract
  44. Thalassemia: the continued challenge. Ann N Y Acad Sci. 2005; 1054:1-10. View Abstract
  45. RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations. Br J Haematol. 2004 Oct; 127(1):105-13. View Abstract
  46. Determination can win the battle. Lancet. 2004 Jul 17-23; 364(9430):301. View Abstract
  47. Acceptance of the 2003 John Howland Award: a journey in clinical research. Pediatr Res. 2004 Aug; 56(2):169-76. View Abstract
  48. Clinical research and the NIH--a report card. N Engl J Med. 2003 Nov 06; 349(19):1860-5. View Abstract
  49. First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. Am J Obstet Gynecol. 2003 Jul; 189(1):171-6. View Abstract
  50. Deferiprone and hepatic fibrosis. Blood. 2003 Jun 15; 101(12):5089-90; author reply 5090-1. View Abstract
  51. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003 May 10; 361(9369):1597-602. View Abstract
  52. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet. 2003 Jan 11; 361(9352):183; author reply 183-4. View Abstract
  53. Clinical research: a tale of two studies. Trans Am Clin Climatol Assoc. 2003; 114:219-30; discussion 230-2. View Abstract
  54. Academic freedom in clinical research. N Engl J Med. 2002 Oct 24; 347(17):1368-71. View Abstract
  55. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood. 2002 Dec 15; 100(13):4649-54. View Abstract
  56. Careers in translational clinical research-historical perspectives, future challenges. JAMA. 2002 May 08; 287(18):2424-7. View Abstract
  57. Educational-debt relief for clinical investigators--a vote of confidence. N Engl J Med. 2002 Jan 31; 346(5):372-4. View Abstract
  58. Comprehensive cancer centres and the war on cancer. Nat Rev Cancer. 2001 Dec; 1(3):240-5. View Abstract
  59. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2001 Sep; 239(9):643-8. View Abstract
  60. Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease. Blood. 2001 Apr 01; 97(7):2145-50. View Abstract
  61. The National Institutes of Health and clinical research: a progress report. Nat Med. 2000 Nov; 6(11):1201-4. View Abstract
  62. Congenital bone marrow failure syndromes. Br J Haematol. 2000 Oct; 111(1):30-42. View Abstract
  63. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood. 1999 Apr 01; 93(7):2217-24. View Abstract
  64. Academia and industry: lessons from the unfortunate events in Toronto. Lancet. 1999 Mar 06; 353(9155):771-2. View Abstract
  65. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med. 1998 Dec 03; 339(23):1711-2; author reply 1713-4. View Abstract
  66. Clinical research: perceptions, reality, and proposed solutions. National Institutes of Health Director's Panel on Clinical Research. JAMA. 1998 Oct 28; 280(16):1427-31. View Abstract
  67. Pioneers and modern ideas. Prospective on thalassemia. Pediatrics. 1998 Jul; 102(1 Pt 3):281-3; discussion 288-9. View Abstract
  68. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997 Sep 01; 90(5):1867-73. View Abstract
  69. The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression. Mol Med. 1996 Nov; 2(6):766-73. View Abstract
  70. Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3. J Biol Chem. 1996 Jun 14; 271(24):14020-7. View Abstract
  71. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore). 1996 Mar; 75(2):77-8. View Abstract
  72. Iron Deficiency Anemia Associated with an Error of Iron Metabolism in Two Siblings: A Thirty Year Follow Up. Hematology. 1996; 1(1):65-73. View Abstract
  73. An orally active iron chelator. N Engl J Med. 1995 Apr 06; 332(14):953-4. View Abstract
  74. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994 Sep 01; 331(9):574-8. View Abstract
  75. Interleukin-3 expression by activated T cells involves an inducible, T-cell-specific factor and an octamer binding protein. Blood. 1993 Feb 15; 81(4):928-34. View Abstract
  76. Academic careers: choice and activity of graduates of a pediatric residency program 1974-1986. Trans Am Clin Climatol Assoc. 1993; 104:180-95; discussion 195-7. View Abstract
  77. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol. 1992 Nov; 20(10):1156-64. View Abstract
  78. A service chief model for general pediatric inpatient care and residency training. Pediatrics. 1992 Apr; 89(4 Pt 1):601-7. View Abstract
  79. Careers chosen by graduates of a major pediatrics residency program, 1974-1986. Acad Med. 1992 Apr; 67(4):272-4. View Abstract
  80. Restoration of phagocyte function by interferon-gamma in X-linked chronic granulomatous disease occurs at the level of a progenitor cell. Blood. 1990 Dec 15; 76(12):2443-8. View Abstract
  81. Intrinsic potential for high fetal hemoglobin production in a Druz family with beta-thalassemia is due to an unlinked genetic determinant. Hum Genet. 1990 Dec; 86(2):175-80. View Abstract
  82. The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood. 1990 Nov 15; 76(10):2052-9. View Abstract
  83. The treatment of Cooley's anemia. Haematologica. 1990 Sep-Oct; 75 Suppl 5:57-65. View Abstract
  84. Treatment of Cooley's anemia. Blood. 1990 Aug 01; 76(3):435-44. View Abstract
  85. Positive and negative elements regulate human interleukin 3 expression. Proc Natl Acad Sci U S A. 1990 Jul; 87(13):5046-50. View Abstract
  86. Regulation of hematopoiesis. Pediatr Res. 1990 May; 27(5):423-31. View Abstract
  87. Oral iron chelators. Semin Hematol. 1990 Apr; 27(2):83-5. View Abstract
  88. Pharmacologic manipulation of fetal hemoglobin in the hemoglobinopathies. Ann N Y Acad Sci. 1990; 612:179-83. View Abstract
  89. The Jeremiah Metzger lecture. Regulation of hematopoiesis. Trans Am Clin Climatol Assoc. 1990; 101:135-53. View Abstract
  90. The beneficence of neonatal hematopoiesis. N Engl J Med. 1989 Oct 26; 321(17):1190-1. View Abstract
  91. Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. Blood. 1989 Oct; 74(5):1525-30. View Abstract
  92. Beta-thalassemia due to two novel nucleotide substitutions in consensus acceptor splice sequences of the beta-globin gene. Blood. 1989 Mar; 73(4):914-8. View Abstract
  93. Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood. 1989 Mar; 73(4):945-51. View Abstract
  94. Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood. 1989 Feb 15; 73(3):688-93. View Abstract
  95. Saudi Arabian sickle cell anemia. A molecular approach. Ann N Y Acad Sci. 1989; 565:143-51. View Abstract
  96. Regulation of the human interleukin-3 gene. Trans Assoc Am Physicians. 1989; 102:240-51. View Abstract
  97. Combinations of purified recombinant colony-stimulating factors are required for optimal hematopoietic differentiation. Trans Assoc Am Physicians. 1988; 101:282-7. View Abstract
  98. Decreased hematopoietic accessory cell function following bone marrow transplantation. Exp Hematol. 1987 Nov; 15(10):1013-21. View Abstract
  99. Leukemia and the regulation of hematopoiesis. Leukemia. 1987 Oct; 1(10):683-96. View Abstract
  100. Stimulation of human hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin 3. J Clin Invest. 1987 Sep; 80(3):818-23. View Abstract
  101. Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. Blood. 1987 Sep; 70(3):716-20. View Abstract
  102. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest. 1987 Aug; 80(2):573-7. View Abstract
  103. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N Engl J Med. 1987 Jan 29; 316(5):244-50. View Abstract
  104. Analysis of high fetal hemoglobin production in sickle cell anemia patients from the Eastern Province of Saudi Arabia. Prog Clin Biol Res. 1987; 251:415-26. View Abstract
  105. Regulation of fetal hemoglobin synthesis in sickle cell anemia. Trans Am Clin Climatol Assoc. 1987; 98:21-8. View Abstract
  106. Investigations of the simian ontogenic switch from fetal to adult hemoglobin at the progenitor cell level. J Clin Invest. 1986 Dec; 78(6):1497-503. View Abstract
  107. High fetal hemoglobin production in sickle cell anemia in the eastern province of Saudi Arabia is genetically determined. Blood. 1986 May; 67(5):1404-10. View Abstract
  108. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest. 1986 Jan; 77(1):74-81. View Abstract
  109. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985 Dec; 66(6):1247-50. View Abstract
  110. Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J Clin Invest. 1985 Sep; 76(3):1286-90. View Abstract
  111. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest. 1985 Jun; 75(6):1999-2005. View Abstract
  112. Determination of the hemoglobin F program in human progenitor-derived erythroid cells. J Clin Invest. 1985 Apr; 75(4):1359-68. View Abstract
  113. Identification of three accessory cell populations in human bone marrow with erythroid burst-promoting properties. J Clin Invest. 1985 Apr; 75(4):1278-84. View Abstract
  114. Current therapy and new approaches to the treatment of thalassemia major. Ann N Y Acad Sci. 1985; 445:248-55. View Abstract
  115. Regulation of fetal hemoglobin synthesis by cell cycle specific drugs. Prog Clin Biol Res. 1985; 191:475-500. View Abstract
  116. Regulation of fetal hemoglobin synthesis in the hemoglobinopathies. Ann N Y Acad Sci. 1985; 445:177-87. View Abstract
  117. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984 Aug; 74(2):652-6. View Abstract
  118. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med. 1984 Apr 05; 310(14):869-73. View Abstract
  119. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia. Trans Assoc Am Physicians. 1984; 97:268-74. View Abstract
  120. Nutrition classics: the Journal of Clinical Investigation, volume 43, 1964. Iron deficiency anemia associated with an error of iron metabolism in two siblings. Nutr Rev. 1983 Oct; 41(10):315-7. View Abstract
  121. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest. 1983 Aug; 72(2):694-706. View Abstract
  122. Synthesis of hemoglobin F in adult simian erythroid progenitor-derived colonies. J Clin Invest. 1982 Oct; 70(4):752-61. View Abstract
  123. Clinical removal of iron. Annu Rev Med. 1982; 33:509-19. View Abstract
  124. Exercise-induced hemolysis in xerocytosis. Erythrocyte dehydration and shear sensitivity. J Clin Invest. 1981 Sep; 68(3):631-8. View Abstract
  125. Heterogeneity of DNA deletion in gamma delta beta-thalassemia. J Clin Invest. 1981 Mar; 67(3):878-84. View Abstract
  126. Control of the simian fetal hemoglobin switch at the progenitor cell level. J Clin Invest. 1981 Feb; 67(2):458-66. View Abstract
  127. The molecular genetics of thalassemia. Adv Hum Genet. 1981; 11:233-80. View Abstract
  128. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980 Aug 28; 303(9):473-8. View Abstract
  129. Aplastic and hypoplastic anemia. Pediatr Clin North Am. 1980 May; 27(2):217-35. View Abstract
  130. New approaches to the transfusion management of thalassemia. Blood. 1980 Jan; 55(1):55-60. View Abstract
  131. F-cell regulation. Ann N Y Acad Sci. 1980; 344:219-32. View Abstract
  132. Monocytes do not inhibit peripheral blood erythroid burst forming unit colony formation. J Clin Invest. 1980 Jan; 65(1):219-23. View Abstract
  133. Prenatal diagnosis of hemoglobinopathies: the New England approach. Ann N Y Acad Sci. 1980; 344:151-64. View Abstract
  134. Prenatal diagnosis of hemoglobinopathies. Clin Perinatol. 1979 Sep; 6(2):275-91. View Abstract
  135. Progress in thalassemia research. Nature. 1979 Jul 26; 280(5720):275-6. View Abstract
  136. The molecular basis of alpha-thalassemias: frequent occurrence of dysfunctional alpha loci among non-Asians with Hb H disease. Cell. 1979 May; 17(1):33-42. View Abstract
  137. Partial deletion of beta-globin gene DNA in certain patients with beta 0-thalassemia. Proc Natl Acad Sci U S A. 1979 May; 76(5):2400-4. View Abstract
  138. Application of endonuclease mapping to the analysis and prenatal diagnosis of thalassemias caused by globin-gene deletion. N Engl J Med. 1978 Jul 27; 299(4):166-72. View Abstract
  139. Antenatal diagnosis of thalassaemia major. Br Med J. 1978 Feb 11; 1(6109):350-3. View Abstract
  140. Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. J Clin Invest. 1978 Feb; 61(2):489-98. View Abstract
  141. Treatment of iron overload in adults with continuous parenteral desferrioxamine. Am J Med. 1977 Dec; 63(6):958-66. View Abstract
  142. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977 08 25; 297(8):418-23. View Abstract
  143. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis. Trans Assoc Am Physicians. 1977; 90:335-41. View Abstract
  144. Prenatal diagnosis of hemoglobinopathies: detection of alpha-thalassemia trait and of sickle cell disease in utero. Hemoglobin. 1977; 1(4):395-400. View Abstract
  145. Fetal research: an investigator's view. Villanova Law Rev. 1977 Jan; 22(2):384-94. View Abstract
  146. Prenatal diagnosis of hemoglobinopathies. A review of 15 cases. N Engl J Med. 1976 Dec 23; 295(26):1437-43. View Abstract
  147. The thalassemias. N Engl J Med. 1976 Sep 23; 295(13):710-4. View Abstract
  148. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med. 1976 Jun 24; 294(26):1421-3. View Abstract
  149. Prenatal diagnosis of sickle-cell anemia and alpha G Philadelphia. Study of a Fetus also at risk for H b S/beta+-thalassemia. N Engl J Med. 1976 May 06; 294(19):1040-1. View Abstract
  150. The acute and transient nature of idiopathic immune hemolytic anemia in childhood. J Pediatr. 1976 May; 88(5):780-3. View Abstract
  151. Molecular pathology of the thalassemias. Adv Intern Med. 1976; 21:97-128. View Abstract
  152. The molecular genetics of thalassemia. Birth Defects Orig Artic Ser. 1976; 12(8):145-59. View Abstract
  153. Expression of the beta-thalassemia gene in the first trimester fetus. Proc Natl Acad Sci U S A. 1975 Sep; 72(9):3633-7. View Abstract
  154. Antenatal diagnosis of hemoglobinopathies: social and technical considerations. Semin Hematol. 1975 Jul; 12(3):305-21. View Abstract
  155. Hemoglobin Syracuse (alpha2beta2-143(H21)His leads to Pro), a new high-affinity variant detected by special electrophoretic methods. Observations on the auto-oxidation of normal and variant hemoglobins. J Clin Invest. 1975 Mar; 55(3):469-77. View Abstract
  156. Thalassemia. Annu Rev Med. 1975; 26:345-51. View Abstract
  157. Progress in the methodology for antenatal diagnosis of the beta chain hemoglobinopathies. Trans Assoc Am Physicians. 1975; 88:168-76. View Abstract
  158. Ethical problems in fetal research. J Gen Educ. 1975; 27(3):165-75. View Abstract
  159. Globin translation in thalassemic bone marrow. Ann N Y Acad Sci. 1974 Nov 29; 241(0):253-61. View Abstract
  160. In utero diagnosis of hemoglobinopathies. Hemoglobin synthesis in fetal red cells. N Engl J Med. 1974 05 09; 290(19):1067-8. View Abstract
  161. Relation of beta to gamma synthesis during the first trimester: an approach to prenatal diagnosis of thalassemia. Pediatr Res. 1974 May; 8(5):553-60. View Abstract
  162. Intrauterine diagnosis of thalassemia. Ann N Y Acad Sci. 1974; 232(0):145-51. View Abstract
  163. Translational control of hemoglobin synthesis in thalassemic bone marrow. Ann N Y Acad Sci. 1974; 232(0):40-3. View Abstract
  164. Effects of cyanate and 2,3-diphosphoglycerate on sickling. Relationship to oxygenation. J Clin Invest. 1973 Oct; 52(10):2542-7. View Abstract
  165. The mortality of acquired aplastic anemia in children. Blood. 1972 Aug; 40(2):153-62. View Abstract
  166. Equal synthesis of - and -globin chains in erythroid precursors in heterozygous -thalassemia. J Clin Invest. 1972 Jul; 51(7):1906-9. View Abstract
  167. Energy metabolism in human erythrocytes. II. Effects of glucose depletion. J Clin Invest. 1972 Jun; 51(6):1547-54. View Abstract
  168. Thalassemia. N Engl J Med. 1972 Mar 16; 286(11):586-94. View Abstract
  169. Changes in fatty acid metabolism after erythrocyte peroxidation: stimulation of a membrane repair process. J Clin Invest. 1972 Feb; 51(2):338-44. View Abstract
  170. Gamma-beta thalassemia: a cause of hemolytic disease of the newborn. N Engl J Med. 1972 Jan 20; 286(3):129-34. View Abstract
  171. Oxidant injury of caucasian glucose-6-phosphate dehydrogenase-deficient red blood cells by phagocytosing leukocytes during infection. J Clin Invest. 1971 Dec; 50(12):2466-73. View Abstract
  172. Amino acid oxidase of leukocytes in relation to H 2 O 2 -mediated bacterial killing. J Clin Invest. 1971 Sep; 50(9):1985-91. View Abstract
  173. Energy metabolism in human erythrocytes. I. Effects of sodium fluoride. J Clin Invest. 1971 Aug; 50(8):1731-7. View Abstract
  174. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. J Clin Invest. 1971 Mar; 50(3):688-99. View Abstract
  175. Endogenous production of carbon monoxide in normal and erythroblastotic newborn infants. J Clin Invest. 1971 Jan; 50(1):1-8. View Abstract
  176. Normal and variant isoenzymes of human blood cell hexokinase and the isoenzyme patterns in hemolytic anemia. Blood. 1970 Aug; 36(2):219-27. View Abstract
  177. Correction of metabolic deficiencies in the leukocytes of patients with chronic granulomatous disease. J Clin Invest. 1970 May; 49(5):865-70. View Abstract
  178. Mild thalassemia: the result of interactions of alpha and beta thalassemia genes. J Clin Invest. 1970 Apr; 49(4):635-42. View Abstract
  179. Mild thalassemia--a guide to therapy. N Engl J Med. 1969 Dec 11; 281(24):1363-4. View Abstract
  180. Unbalanced globin chain synthesis in alpha-thalassemia heterozygotes. Ann N Y Acad Sci. 1969 Nov 20; 165(1):288-94. View Abstract
  181. Globin chain synthesis in the alpha thalassemia syndromes. J Clin Invest. 1969 Nov; 47(11):2512-22. View Abstract
  182. Failure of nitro blue tetrazolium reduction in the phagocytic vacuoles of leukocytes in chronic granulomatous disease. J Clin Invest. 1969 Oct; 48(10):1895-904. View Abstract
  183. Influence of hemoglobin precipitation on erythrocyte metabolism in alpha and beta thalassemia. J Clin Invest. 1969 Jan; 48(1):33-41. View Abstract
  184. Stages in the incorporation of fatty acids into red blood cells. J Clin Invest. 1968 May; 47(5):1096-108. View Abstract
  185. Erythrocyte production and metabolism in anephric and uremic men. Ann N Y Acad Sci. 1968 Mar 29; 149(1):539-43. View Abstract
  186. Hemoglobin F and beta thalassemia. Science. 1967 Sep 01; 157(3792):1079. View Abstract
  187. THE METABOLISM OF THE INDIVIDUAL C14 LABELED HEMOGLOBINS IN PATIENTS WITH H-THALASSEMIA, WITH OBSERVATIONS ON RADIOCHROMATE BINDING TO THE HEMOGLOBINS DURING RED CELL SURVIVAL. J Clin Invest. 1965 Feb; 44:315-25. View Abstract
  188. ERYTHROPOIESIS IN ANEPHRIC MAN. J Clin Invest. 1964 Nov; 43:2158-65. View Abstract
  189. THALASSEMIA TRAIT. GENETIC COMBINATIONS OF INCREASED FETAL AND A2 HEMOGLOBINS. N Engl J Med. 1964 Jun 04; 270:1212-7. View Abstract
  190. IRON DEFICIENCY ANEMIA ASSOCIATED WITH AN ERROR OF IRON METABOLISM IN TWO SIBLINGS. J Clin Invest. 1964 Mar; 43:510-21. View Abstract
  191. THE TURNOVER OF HEMOGLOBINS A, F, AND A(2) IN THE PERIPHERAL BLOOD OF THREE PATIENTS WITH THALASSEMIA. J Clin Invest. 1963 Nov; 42(11):1678-88. View Abstract
  192. THE EFFECT OF ANDROGENS ON SOME ASPECTS OF BODY COMPOSITION AND ERYTHROPOISIS IN OCTOGENARIAN MALES. Ann N Y Acad Sci. 1963 Sep 26; 110:965-77. View Abstract
  193. Erythroid cell maturation and hemoglobin synthesis in megaloblastic anemia. J Clin Invest. 1962 May; 41:1086-93. View Abstract
  194. The synthesis of heme and globin in the maturing human erythroid cell. J Clin Invest. 1961 Jun; 40:940-6. View Abstract
  195. Hypochromic anemia and hemochromatosis--response to combined testosterone, pyridoxine, and liver extract therapy. Trans Am Clin Climatol Assoc. 1961; 73:121-35. View Abstract
  196. The passage of ammonia across the blood-brain-barrier and its relation to blood pH. J Clin Invest. 1958 Dec; 37(12):1724-8. View Abstract

Contact David G. Nathan

Print Profile